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Renal and hemodynamic responses to bumetanide in hypertension:
Effects of nitrendipine. The effects of a calcium antagonist on the
response to a loop diuretic were tested in eight hypertensive patients
while they received 120 mmol . 24 hr of dietary Na. Nitrendipine (N;
20 mg) or placebo (F) was administered twice daily for five days and
bumetanide (B; I mg, i.v.) for the last three days of each period.
Cardiac index (CI) was measured during tilt. B alone significantly (P <
0.05; N = 7) reduced CI and increased total peripheral resistance; N
prevented these effects of B. Neither drug altered BP consistently.
Although three days of B increased plasma renin activity (PRA) during
P and N, it increased plasma aldosterone (RAId,,) only during P (P. 4.4
1.3 to 7.6 1.0; P <0.05. N, 5.7 1.3 to 6.0 1.3; pg• Iiter; NS).
B increased Na excretion without changing GFR or RPF; this was
followed by 18 hours of decreased renal Na excretion. These actions
were unchanged by N. N did not change the cumulative excretion of B
(P, 268 35 vs. N, 217 21 g) or the relationship between Na
excretion and the log of B excretion. However, Na excretion was
increased (P < 0.05) by 40 to 60% in the six hour period following the
first two doses of N. Therefore, the cumulative Na balance was more
negative during five days ofN(P, —47 17 vs. N, —108 24mmol;P
< 0.05). The effect of N and B on Na balance were independent. In
conclusion, short-term administration of N: I) increases Cl and reduces
TPRI in the post-diuretic state; 2) blunts B-induced increase in Aldo
without modifying the rise in PRA; 3) does not change B kinetics or
dynamics or the post-diuretic period of renal Na retention; 4) causes
negative Na balance which is additive with that produced by B.
Calcium antagonists and diuretics are used with increasing
frequency to treat patients with hypertension or coronary artery
disease. However, there is little quantitative information about
how these drugs interact. Studies of their antihypertensive
interaction have produced conflicting results. Sever and Poulter
[11 demonstrated that a thiazide produced a further fall in the
BP of hypertensive subjects receiving a calcium antagonist. In
contrast, Cappuccio et al [2] found no significant change and
most other trials have shown either no additional effect or a less
than additive action [2—4]. The basis for this apparently unfa-
vorable interaction in the treatment of hypertension has not yet
been established. Since both classes of drugs are natriuretic
[5—8], it has been suggested that the antagonistic effect in
hypertension might be explained if calcium antagonists blocked
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the salt-depleting actions of diuretics [4]. Alternatively, calcium
antagonists might modify diuretic kinetics. Moreover, a stable
BP might conceal important additional effects of these drugs on
cardiac output or total peripheral resistance. Thus, loop diuret-
ics given to patients with cardiac failure can stimulate the
renin-angiotensin system sufficiently to raise the peripheral
vascular resistance and BP [9]. Since calcium antagonists can
blunt angiotensin-induced pressor responses [10, 11], they
might also blunt these potentially adverse hemodynamic effects
of diuretics. Therefore, this study was designed to investigate
the interaction between these two classes of drugs in further
detail. We examined the effects of a calcium antagonist (nitren-
dipine) on the salt-depleting and hemodynamic actions of a loop
diuretic (bumetanide) in hypertensive subjects. Measurements
were also made of key hormones and drug kinetics to explore
further potential mechanisms of interaction.
Previous studies of the "diuretic braking phenomenon" [12]
have shown that during liberal salt intake, progressive Na
depletion induced by a loop diuretic is curtailed by a reduction
in Na excretion in the post-diuretic period. In contrast, during
severe dietary salt restriction, it is curtailed by a decreased
natriuretic response to the diuretic [13—151. This post-diuretic
salt retention limits the efficacy of diuretics and persists despite
blockade of angiotensin II formation or alpha,-adrenoreceptors.
Therefore we investigated whether a calcium antagonist modi-
fied this phenomenon.
Methods
Studies were performed on seven men and one woman aged
45 to 65 years. All drugs were withdrawn one month prior to the
study. Entry criteria included: a diastolic blood pressure (DBP)
of 95 to 109 mm Hg on two separate occasions measured in the
clinic two to four weeks after withdrawal of antihypertensive
drugs; a diagnosis of essential hypertension; normal values for
hemogram, blood urea and electrolytes, blood sugar, and uri-
nalysis. Patients with only mild hypertension were selected to
obviate the effects of an abrupt fall in BP produced by the
calcium antagonist on changes in hemodynamics or Na balance.
The study was passed by the Institutional Review Board of the
University of Florida and VA Medical Center. All subjects gave
informed consent.
Patients were admitted to the Clinical Research Center Met-
abolic Balance Ward for 14 days. They received a regulated diet
with weighed quantities of food which provided 20 mmol . 24
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hr of Na, 70 mmol . 24 hr of potassium (K) and 1.1
g. kg . 24 hr' of protein. This was supplemented with 6
g. 24 hr of NaC1 given in equal quantities with breakfast (7
a.m.), lunch (12 midday) and dinner (6 p.m.). Therefore, the
daily intake of Na was 120 mmol. Water was provided ad
libitum. Subjects refrained from smoking or drinking alcohol.
After an initial two-day washout period, for the next five days
subjects received either 20 mg of nitrendipine (Baypress; Miles
Pharmaceuticals, West Haven, Connecticut, USA) at 6 a.m.
and 6 p.m., or matching placebo. Thereafter, there was a
second two-day washout period after which they were crossed
over to receive the other agent (nitrendipine or placebo).
Allocation to receive nitrendipine or placebo first was by
random number (4 received nitrendipine first and 4 received
placebo). The study was conducted under double-blind condi-
tions. At 9a.m. on the last three days of each week the patients
also received a daily intravenous injection of 1 mg of bumet-
anide (Bumex; Hoffmann-LaRoche, Inc., Nutley, New Jersey,
USA).
Urine was collected each six hours beginning at 6 a.m. on the
third day of each week. At 8 a.m., the patients were seated
quietly for two minutes while blood pressure (BP) was mea-
sured by a sphygmomanometer and heart rate (HR) was re-
corded.
Standard two-dimensional and pulsed Doppler echocardio-
grams [16] were performed at 11:30 a.m. on day 6 of each week;
this was 2-1/2 hours after the second daily dose of bumetanide.
The subjects were positioned at a 60° incline on a tilt table for 30
minutes before making the measurements. With the subject
lying in the left lateral supine position, chamber dimensions, left
ventricular wall thickness, ejection fraction and cardiac output
were measured. The mean arterial pressure (MAP; diastolic
plus 1/3 pulse pressure) and HR were recorded simultaneously.
The fifth Korotkoff sound was used for diastolic BP. The total
peripheral resistance index (TPRI) was calculated from MAP
and cardiac index (CI). Seven of the subjects were also studied
under the same conditions of diet and tilt before and 2-1/2 hours
after administration of bumetanide (I mg i.v.) alone to establish
the effects of the diuretic itself.
On days 5 and 7 of each week, the renal responses to
intravenous bumetanide were studied. With the subjects seated,
a vein was cannulated in each forearm for intravenous infusion
and blood sampling. At 6 a.m., the patients received 350 ml of
water by mouth and a light breakfast. An intravenous infusion
of dextrose solution (5 g . 100 ml ') containing [99"Tc]-dieth-
ylenetriaminepentaacetic acid (DTPA; 0.013 pCi kg' min';
Metaphysics, Inc., Richmond, California, USA) and sodium
paraaminohippurate (PAH; 0.20 mg. kg-I . min; Merck,
Sharp and Dohme, West Point, Pennsylvania, USA) was deliv-
ered at I ml . min, Loading doses of 1.0 pCi . kg' DTPA
and 8.8 mg. kg' PAH were administered at the beginning of
the infusion. After one hour for equilibration, there was a two
hour basal clearance period. Thereafter bumetanide (I mg;
Bumex, Hoffman LaRoche, Inc.) was given as an intravenous
bolus over two minutes. There followed five 30-minute clear-
ance periods; blood was sampled at the midpoints of each.
Samples for plasma renin activity (PRA) and plasma aldoste-
rone concentration (PAIdO) were drawn before the first dose and
150 minutes after the last dose of bumetanide.
Routine chemical methods have been described [13—IS]. The
PRA was estimated from the quantity of angiotensin I generated
over a 90 minute incubation at 25°C (Travenol-Genetech Diag-
nostics, Cambridge, Massachusetts, USA). The Ajdo was
estimated using a radioimmunoassay (Diagnostic Products
Corp., Los Angeles, California, USA). Blood for assay of total
catecholamine concentration (at) was drawn into tubes con-
taining EGTA and glutathione and maintained on ice. Plasma
was assayed using a radioenzymic method (Amersham Biomed-
ical Research, Arlington Heights, Illinois, USA) for measure-
ment of total catecholamines. All plasma samples for hormone
assay were stored at —70°C.
A high-pressure liquid chromatographic (HPLC) method for
quantitation of bumetanide in urine was developed from a prior
method to maximize the sensitivity, shorten the sample prepa-
ration time and decrease instrumentation requirements [171.
After addition of the 4-benzyl bumetanide derivative as an
internal standard (supplied by LaRoche Pharmaceuticals) urine
was extracted once with ethyl acetate at an acidic pH, sepa-
rated, evaporated to dryness, reconstituted with methanol, and
chromatographed using a reversed-phase, C-l8, radial-com-
pression cartridge with fluorescence detection. Sensitivity lim-
its were approximately 1 ng. ml of bumetanide in urine, with
a coefficient of variation for identical urine samples not exceed-
ing 4% [17].
The glomerular filtration rate (GFR) was estimated from
DTPA clearance and the renal plasma flow (RPF) from Hip-
puran clearance. The fractional excretion of sodium (FENa)was
calculated by dividing the urine-to-plasma concentrations of Na
by DTPA.
Results were assessed by paired t-tests comparing bumet-
anide-induced changes during nitrendipine and placebo periods.
The values were considered statistically significant at P < 0.05
[181. An analysis of variance (ANOVA) with repeated measures
was used to assess the effects of nitrendipine and days of
diuretic administration on bumetanide excretion, and the effects
of nitrendipine and bumetanide on cumulative Na balance.
Results
All subjects completed the protocol. One complained of
headache during nitrendipine but there were no other adverse
effects. All subjects had DBP's above 95 mm Hg on two
separate occasions in the clinic. However, under conditions of
regulated dietary intake in hospital, three subjects had DBP's
that were only 90 to 95 mm Hg.
The hemodynamic effects of bumetanide alone were investi-
gated in seven subjects studied under the same conditions of
head-up tilt before and 2-1/2 hours after bumetanide (1 mg i.v.).
Although bumetanide did not change the MAP (112 S to 112
5mm Hg), the HR was increased (81 2 to 97 4; P <0.01),
the CI was reduced (2.32 0.20 to 1.69 0.12; P <0.01) and
TPRI was increased (2,690 315 to 3,812 420 dynes
sec cm5; P < 0.05). Figure 1 shows hemodynamic data
obtained during 60° head-up tilt 2-1/2 hours after bumetanide
plus placebo compared to a similar time after bumetanide plus
nitrendipine. Nitrendipine reduced the MAP of seven of eight
subjects in the post-diuretic state, although the overall change
was not statistically significant. However, the HR and CI were
consistently increased by nitrendipine and the TPRI was re-
duced. Therefore, the maintenance of BP after nitrendipine was
accomplished by a greater cardiac output but at a sharply
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Table 1. Plasma total catecholamines, renin activity and aldosterone
concentration with bumetanide: Effects of nitrendipine
Placebo Nitrendipine
Before After B Before After B
'Catpg m1'
PRA
ngAI. m1' hr'
Aldo
ng• dl-'
310 35
6.5 2.4
4.4 1.3
480 90
12.3 33a
7.6 1.oa
520 75b
5•3 2.1
5.7 1.3
670 I05
15.5 3.8a
6.0 1,3
Mean SEM values (N = 8) for data obtained before the first dose of
bumetanide (before) and 2-1/2 hr after the third dose (after B).
a P < 0.05 comparing before and after bumetanideb P < 0.05 comparing placebo and nitrendipine periods
reduced total peripheral resistance. Nitrendipine effectively
prevented the fall in cardiac output and rise in peripheral
resistance induced by the diuretic alone.
The values for Cat were higher during nitrendipine than
placebo (Table 1). Comparison of hormone measurements made
in the basal state before bumetanide administration with values
obtained 150 minutes after the third bumetanide injection dem-
onstrated a consistent increase in PCat and PRA during placebo
and nitrendipine administration. Whereas AIdo also increased
consistently with bumetanide during placebo, this change was
not seen during nitrendipine administration.
In the basal state before the daily bumetanide injection, the
MAP again tended to be 4 to 9 mm Hg lower during nitrendipine
than placebo, although these differences were not statistically
significant. Table 2 shows data before and 2-1/2 hours after
bumetanide. Two patterns were apparent in the basal UNaV.
First, nitrendipine increased the basal UNaV, as shown by
higher values (P < 0.05) compared to placebo on both the first
and third days of bumetanide (B 1 and B3). Second, the basal
UNaV was reduced (P < 0.02) on days B3 compared to B!
during both the placebo and nitrendipine periods. There were
no associated changes in the basal values of GFR or RPF.
Bumetanide caused a sharp increase in UNaVwithout consis-
Table 2. Mean blood pressure, Na excretion and renal
hemodynamics with bumetanide: Effects of nitrendipine
Placebo Nitrendipine
Days BI B3 B! B3
MAP mm Hg
Basal 180.0 3.3 103.1 3.3 102.4 1.7 99.5 3.1
Bumetanide 109.4 3.7 105.8 3.9 100.7 3.6 101.4 3.4
Change with B +1.4 1.2 +2.7 1.0 —1.7 2.5 +1.9 1.7
UNV iunol . min'
Basal 117 22 59 8 167 44 82 12
Bumetanide 820 59 633 47 741 65 638 41
Change with B +703 50 +574 46 +574 68 +556 39
GFR ml. min'
Basal 84±7 83±6 88±9 82±8
Bumetanide 86 8 81 5 80 4 90 9
Change with B +2 11 —l 6 —8 10 +8 11
RPF ml. min'
Basal 386 25 346 30 390 47 370 37
Bumetanide 410 38 353 27 374 26 415 39
ChangewithB +24±52 +7±28 —16±41 +45±48
Mean SEM values (N = 8). Data were obtained over 2 hr before and
2-1/2 hr following bumetanide (I mg). Patients received placebo or
nitrendipine (20 mg) before starting the basal measurements. Bl and B3
refer to the first and third days of bumetanide administration. There
were no significant effects of nitrendipine on the changes produced by
bumetanide. However, basal UNaV was higher (P > 0.05) on days Bl
and B3 with nitrendipine compared to placebo.
tent effects on GFR or RPF; these responses were unaltered by
nitrendipine. Moreover, examination of the time course of
changes from the 30-minute urine collection also failed to
disclose any effects of nitrendipine.
The cumulative excretion of bumetanide averaged 19% of the
injected dose over the first 2-1/2 hours and 24% over 24 hours
(Table 3). This was unaffected by nitrendipine and was not
different between the first and third doses of bumetanide. An
analysis of variance with repeated measures demonstrated no
significant effects of nitrendipine or days of bumetanide admin-
istration on bumetanide excretion over 2-1/2 or 24 hours (F
values below 1; NS).
The increase in fractional Na excretion (FENa) was related to
E
120
110
100
90
a—
E
p<0.01
I
120
110
100
90
S
0
P'zO.05 P<0.01r, 3,000
2.6
2.4
2.2
a
2.500
2.0
1.8 ,
2,000
1.6 a..I-
1.4
1.2 1,500
a— a-.-
Fig. 1. Mean SEM values for heart rate,
mean blood pressure, cardiac index and total
peripheral resistance index. Measurements
were made 5-1/2 hours after placebo (diagonal
shading) or nitrendipine (cross-hatched
shading). Subjects had received bumetanide
2-1/2 hrs previously and were tilted 60 degrees
upright for 20 mm before measurements were
made.
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Placebo Nitrendipine
Day I of bumetanide
First 2-1/2 hr 205 29 181 19
24 hr 265 36 220 21
Day 3 of bumetanide
First 2-1/2 hr 184 22 198 25
24 hr 230 22 262 31
Fig. 2. Mean SEM values for increases in fractional excretion of
sodium as a function of renal bumetanide excretion (log scale). Data
are shown for five 30 mm periods following the first intravenous dose of
bumetanide given during placebo (0) or nitrendipine (S).
the rate of bumetanide excretion (log scale, Fig. 2). The
maximal effect (responsiveness) was not changed by nitren-
dipine, nor was there any consistent change in the intercept of
the linear part of the relationship (sensitivity).
Before bumetanide, UNaV was 40 to 60% higher in the two
six-hour periods following nitrendipine administration than the
corresponding periods during placebo (Fig. 3). This natriuretic
effect was less evident on the second day of nitrendipine
administration. Bumetanide increased UNUV substantially on
each day leading to a negative Na balance in the six hours after
the diuretic (indicated by solid shading, Fig. 3). However,
during the subsequent 18 hours, UNaV was reduced well below
the level of intake resulting in a positive Na balance during this
period (indicated by diagonal shading in Fig. 3). The patterns of
bumetanide-induced natriuresis followed by renal Na conserva-
tion were quite comparable during placebo and nitrendipine
administration. As in previous studies [19], UKV followed a
similar pattern of diuretic-induced loss followed by renal reten-
tion of K and was not affected by nitrendipine (data not shown).
During placebo administration, the balance for Na was not
I Placebo BID
Nitrendipine 20 mg BID
FIg. 3. Mean SEM values for 6-hourly renal sodium excretion during
administration of placebo or nit rendipine. Data are shown as the mean
of two pre-diuretic 24 hr periods, and for the 3 days on which
bumetanide was given (BI, B2, and B3). The level of Na intake is
indicated by the broken horizontal line. Negative Na balance is indi-
cated by solid shading and positive Na balance by diagonal shading. *p
<0.05 comparing nitrendipine and placebo periods.
significantly different from zero before bumetanide administra-
tion (Fig. 4). The nitrendipine-induced natriuresis led to a
modest negative Na balance; by the end of the first day of
nitrendipine administration, Na balance was 45 18 mmol
more negative during nitrendipine than placebo (P < 0.05).
Natriuresis was more variable on the second day of nitrendipine
administration and differences in cumulative Na balances were
not statistically significant. The first dose of bumetanide pro-
duced a negative Na balance which was similar during both
placebo and nitrendipine phases and was maintained over the
subsequent three days. The 45 mmol of Na loss induced by the
first dose of nitrendipine persisted throughout the period of
diuretic administration; on the last day of bumetanide, Na
balance was 61 25 mmol (P < 0.05) more negative during
nitrendipine than placebo. An ANOVA demonstrated signifi-
Table 3. Cumulative excretion of bumetanide (sg)
Mean SEM values (N = 8) for cumulative renal excretion of
unchanged bumetanide. Data are shown for the first 2-1/2 hr and the
entire 24 hr after injection of 1 mg of bumetanide. There were no
significant effects of nitrendipine.
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cant (P < 0.05) effects of nitrendipine and bumetanide on Na
balance, but no interaction between them (F = 0.7; NS).
Discussion
The main new findings of this study were that in patients with
mild hypertension nitrendipine, given during orthostatic stress
and in the post-diuretic state, increased the cardiac output and
reduced the peripheral resistance. This reversed the hemody-
namic effects produced by the diuretic itself. Nitrendipine
interrupted bumetanide-induced increases in Aldo without
modifying the stimulation of PRA or 1Cat Bumetanide dynam-
ics and kinetics were not perturbed by nitrendipine. Over a five
day period, an initial Na loss induced by nitrendipine was
additive with that produced by bumetanide.
During the first few days of thiazide treatment for hyperten-
sion, there is a fall in cardiac output and a rise in peripheral
resistance, although this effect wanes during prolonged therapy
[20]. Our results show a similar early hemodynamic response to
a loop diuretic. Intravenous doses of loop diuretics given for
cardiac failure can also reduce CI because of an abrupt rise in
TPRI [9]. This adverse hemodynamic response, which limits
the therapeutic use of loop diuretics in this setting, has been
attributed to activation of the renin-angiotensin-aldosterone
axis and the sympathetic nervous system [9]. Calcium antago-
nists can prevent the rise in vascular resistance in response to
infusions of angiotensin II [10, Il] vasopressin, catecholamines
[21, 22] or reflex activation of the sympathetic nervous system
[23]. In mild hypertension, calcium antagonists alone have little
effect on CI or TPRI during rest, although they can cause
marked increases in CI and vasodilation during reflex stimula-
tion produced by exercise [24]. Therefore, calcium antagonists
might prevent the adverse increase in peripheral resistance
caused by loop diuretics, although this has not been investi-
gated previously. The present study was undertaken during
orthostatic stress to activate the neural and humeral mecha-
nisms fully. The increases in Cat and PRA produced by
bumetanide confirmed that these systems were indeed activated
by the diuretic. Nitrendipine reversed not only the sharp rise in
peripheral resistance produced by the diuretic, but also the fall
in cardiac output consistent with blockade of activated periph-
eral vasoconstrictor mechanisms. Of interest was the finding
that the MAP following the diuretic was similar during the
placebo and nitrendipine periods, despite widely different val-
ues for cardiac output and peripheral resistance (Fig. I). There-
fore, important hemodynamic interaction between these two
classes of drugs can occur that may not be appreciated by
measurement of BP alone, as in some previous studies [1—3]. It
will be important to determine whether similar hemodynamic
interactions are apparent during more prolonged administration
of thiazides and calcium antagonists, since these classes of
drugs are currently recommended as first-line treatment for
hypertension [25].
In a previous study of patients with mild hypertension
admitted to hospital [8), the antihypertensive response to ni-
trendipine was modest. In the present study, there was no
significant effect of nitrendipine on MAP (Table 2). This may
relate to the relatively young age, somewhat restricted level of
dietary salt intake and to the mild degree of hypertension of our
subjects. Thus, the antihypertensive response to calcium antag-
onists has been reported in some studies to vary directly with
age, dietary salt intake and ambient BP [26—28]. Moreover, the
full antihypertensive response to nitrendipine can take up to
three weeks to develop [29].
Calcium antagonists blunt the rise in aldosterone secretion
provoked by infusion of angiotensin II [10]. This may explain
the interruption of diuretic-induced increases in PAIdO by nitren-
dipine which occurred despite a sharp increase in PRA. Hy-
peraldosteronism can contribute to the adverse effects of long-
term diuretic therapy on serum potassium concentration and
metabolic alkalosis [30]. Therefore, a moderation of diuretic-
induced hyperaldosteronism by calcium antagonists could be
beneficial. Indeed, a blunting of angiotensin lI-induced pressor
responses and aldosterone secretion has been shown in hyper-
tensive subjects during established verapamil therapy [31].
The first dose of a calcium antagonist given to patients with
established hypertension usually increases RPF [32]. During
prolonged therapy, persistent increases in RPF are seen in some
studies [33] whereas others report a return to baseline values
[6]. The absence of a consistent rise in GFR or RPF with
nitrendipine in this study may relate to the timing of the study
after the third dose of the drug or to the mild degree of
hypertension, since these drugs have little effect on renal
hemodynamics at normal levels of BP [7, 34]. Moreover,
increases in RPF are more pronounced in hypertensive patients
with reductions in GFR below 80 mI/mm [34], Alternatively,
there may be a heterogeneity of renal vascular responses to
Bumetanide 1 mg daily
E
E
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+
'Uz
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'U
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0
+ 20
-20
-40
—60
—80
—100
—120
—140
—2 —1 81 82 B3
Time, days
Fig. 4. Mean SEM values for cumulative 24 hr Na balance during
placebo (solid lines) and nitrendipine administration (broken lines).
Data are shown for 2 days before and 3 days during bumetanide
administration (BI, B2, and B3).
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term studies do not support the suggestion that calcium antag-
onists may interrupt diuretic-induced salt loss [41.
In conclusion, the present short-term study in hypertensive
subjects has highlighted several points of interaction between
loop diuretics and calcium antagonists which may have clinical
significance. Thus, during orthostatic stress, nitrendipine can
reverse the increase in peripheral resistance and reduction in
cardiac output provoked by a loop diuretic. This may be
valuable, especially in patients with impaired cardiac reserve in
whom a fall in output may have adverse consequences. Inter-
ruption of diuretic-induced aldosterone secretion, if sustained
during prolonged therapy, could counter some adverse effects
of diuretics attributed to hyperaldosteronism. Finally, nitren-
dipine and bumetanide had additive Na-depleting actions during
modest dietary salt restriction.
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